Featured Press Releases

Neurocrine Biosciences Launches INGREZZA® SPRINKLE (valbenazine) Capsules.

Neurocrine Biosciences Launches INGREZZA® SPRINKLE (valbenazine) Capsules.

Eximia Research Network expands into Virginia by integrating Tidewater Clinical Research

Eximia Research Network expands into Virginia by integrating Tidewater Clinical Research

  • 31 Jul 2024

Eximia Research announces the integration of Tidewater Clinical Research into its national network of...

Scientific article highlights Namodenoson as promising for advanced liver cancer and MASH

Scientific article highlights Namodenoson as promising for advanced liver cancer and MASH

HOOKIPA Pharma announces the completion of enrollment in its Phase 1b clinical trial evaluating HB-500 for the treatment of HIV

HOOKIPA Pharma announces the completion of enrollment in its Phase 1b clinical trial evaluating HB-500 for the treatment of HIV

S&E Bio Secures Korea’s First Approval for a Clinical Trial of Exosome-Based Therapy

S&E Bio Secures Korea’s First Approval for a Clinical Trial of Exosome-Based Therapy

Vector Laboratories Appoints Ashley Scholz as Vice President of Marketing

Vector Laboratories Appoints Ashley Scholz as Vice President of Marketing

Spruce Biosciences Reports Long-Term Data Showing Efficacy and Safety of Tralesinidase Alfa in Sanfilippo Syndrome Type B

Spruce Biosciences Reports Long-Term Data Showing Efficacy and Safety of Tralesinidase Alfa in Sanfilippo Syndrome Type B

  • Spruce Biosciences, Inc.
  • 18 Aug 2025
Izalontamab Brengitecan Receives FDA Breakthrough Therapy Designation for Advanced EGFR-Mutated NSCLC

Izalontamab Brengitecan Receives FDA Breakthrough Therapy Designation for Advanced EGFR-Mutated NSCLC

  • SystImmune, Inc.
  • 18 Aug 2025
New Survey Shows Pediatricians Strongly Prefer Genexa’s Ingredients Over Leading Children’s Tylenol® Products

New Survey Shows Pediatricians Strongly Prefer Genexa’s Ingredients Over Leading Children’s Tylenol® Products

  • Genexa
  • 15 Aug 2025
Proving the strength of its drug-delivery platform, the Daewoong Therapeutics Microneedle Patch achieves best-in-class bioavailability

Proving the strength of its drug-delivery platform, the Daewoong Therapeutics Microneedle Patch achieves best-in-class bioavailability

  • Daewoong Therapeutics Inc
  • 13 Aug 2025
Abcentra LLC Commences Phase 2b

Abcentra LLC Commences Phase 2b 'FORTIFY' Trial with First Patient Dosed, Evaluating Orticumab for Cardiovascular Disease

  • Abcentra
  • 12 Aug 2025
Viatris announces the approval of the first generic iron sucrose injection in the U.S

Viatris announces the approval of the first generic iron sucrose injection in the U.S

  • Viatris Inc.
  • 11 Aug 2025
Webinar: Leverage AI for Operational Excellence and Strategic Cost Management

Most Popular
August   2025
M T W T F S S
        1 2 3
4 5 6 7 8 9 10
11 12 13 14 15 16 17
18 19 20 21 22 23 24
25 26 27 28 29 30 31

User Area

Discover

Engage with Us

© 2024 Pharmaceutical Era — A product of HISSM. All Rights Reserved.